Business Description
Soligenix Inc
NAICS : 325412
SIC : 2834
ISIN : US8342236044
Total Employee Number:
14Description
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 18.27 | |||||
Equity-to-Asset | 0.45 | |||||
Debt-to-Equity | 0.11 | |||||
Debt-to-EBITDA | -0.03 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 69.3 | |||||
3-Year EPS without NRI Growth Rate | 69.7 | |||||
3-Year FCF Growth Rate | 69.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 28.89 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 23.77 | |||||
9-Day RSI | 34.68 | |||||
14-Day RSI | 38.63 | |||||
3-1 Month Momentum % | -63.26 | |||||
6-1 Month Momentum % | -70.66 | |||||
12-1 Month Momentum % | -65.37 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.81 | |||||
Quick Ratio | 1.81 | |||||
Cash Ratio | 1.67 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -281.3 | |||||
Shareholder Yield % | -155.75 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -255.68 | |||||
ROA % | -133.72 | |||||
ROIC % | -1966.4 | |||||
3-Year ROIIC % | -17.29 | |||||
ROC (Joel Greenblatt) % | -3682.82 | |||||
ROCE % | -260.59 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 1.28 | |||||
Price-to-Tangible-Book | 1.3 | |||||
EV-to-EBIT | 0.01 | |||||
EV-to-Forward-EBIT | 5.97 | |||||
EV-to-EBITDA | 0.01 | |||||
EV-to-Forward-Revenue | 4.13 | |||||
EV-to-FCF | 0.01 | |||||
| Price-to-Net-Current-Asset-Value | 1.45 | |||||
| Price-to-Net-Cash | 1.79 | |||||
Earnings Yield (Greenblatt) % | No Debt | |||||
FCF Yield % | -193.47 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SNGX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Soligenix Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.967 | ||
| Beta | 1.7828 | ||
| 3-Year Sharpe Ratio | -0.03 | ||
| 3-Year Sortino Ratio | -0.05 | ||
| Volatility % | 243.71 | ||
| 14-Day RSI | 38.63 | ||
| 14-Day ATR ($) | 0.043679 | ||
| 20-Day SMA ($) | 0.40579 | ||
| 12-1 Month Momentum % | -65.37 | ||
| 52-Week Range ($) | 0.28 - 6.2299 | ||
| Shares Outstanding (Mil) | 14.82 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Soligenix Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Soligenix Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 120 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 36 days | ||
| General meeting for 2026 | 2026-07-17 09:00 | In 9 days | ||
| First quarter earnings results for 2026 | 2026-05-08 | 0.31 (-7.17%) | ||
| Annual report for 2025 | 2026-03-31 | 1.11 (-2.63%) | ||
| Fourth quarter earnings results for 2026 | 2026-03-31 | 1.11 (-2.63%) | ||
| Third quarter earnings results for 2025 | 2025-11-07 | 1.28 (-6.57%) | ||
| Second quarter earnings results for 2025 | 2025-08-14 | 2.45 (-1.61%) | ||
| General meeting for 2025 | 2025-06-20 09:00 | 1.79 (-0.83%) | ||
| First quarter earnings results for 2025 | 2025-05-09 | 1.97 (+3.68%) |
Show
Entries
Soligenix Inc Frequently Asked Questions
What is Soligenix Inc(SNGX)'s stock price today?
The current price of SNGX is $0.38. The 52 week high of SNGX is $6.23 and 52 week low is $0.28.
When is next earnings date of Soligenix Inc(SNGX)?
The next earnings date of Soligenix Inc(SNGX) is 2026-08-14 Est..
Does Soligenix Inc(SNGX) pay dividends? If so, how much?
Soligenix Inc(SNGX) does not pay dividend.
Guru Commentaries on NAS:SNGX
No articles.
Press Release
Articles on Soligenix Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers